Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flurpiridaz F 18
- Development stage
- Approved
- Lead developer
- GE Healthcare
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Flurpiridaz F 18 is a cyclotron-produced radioactive diagnostic agent used for positron emission tomography (PET) myocardial perfusion imaging (MPI) in adults with known or suspected coronary artery disease to evaluate for myocardial ischemia and infarction. It is administered intravenously under rest or stress conditions (pharmacologic or exercise). Flurpiridaz F 18 is an analog of the mitochondrial complex I inhibitor pyridaben; it binds to heart tissue with biologically active mitochondria, resulting in higher radioactivity in viable myocardium compared to infarcted tissue. The drug exhibits high myocardial extraction and retention, providing high-resolution images for the assessment of coronary artery disease. The primary mechanism of action involves its uptake by myocardium proportional to blood flow and binding to mitochondrial complex I within heart cells[1][2][3][7].
- Brand names
- Flyrcado
- Other names
- 2-tert-butyl-4-chloro-5-[[4-(2-(^18^F)fluoranylethoxymethyl)phenyl]methoxy]pyridazin-3-one
02
Targets
ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on Flurpiridaz F 18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flurpiridaz F 18.